194 related articles for article (PubMed ID: 28154416)
1. Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients.
Liu R; Zeng Y; Zhou CF; Wang Y; Li X; Liu ZQ; Chen XP; Zhang W; Zhou HH
Sci Rep; 2017 Feb; 7(1):18. PubMed ID: 28154416
[TBL] [Abstract][Full Text] [Related]
2. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
3. A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
Song J; Zhang W; Wang S; Liu K; Song F; Ran L
Int J Oncol; 2018 Aug; 53(2):866-876. PubMed ID: 29749482
[TBL] [Abstract][Full Text] [Related]
4. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity.
Feng LL; Shen FR; Zhou JH; Chen YG
Gene; 2019 May; 696():105-112. PubMed ID: 30738960
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.
Zhou M; Sun Y; Sun Y; Xu W; Zhang Z; Zhao H; Zhong Z; Sun J
Oncotarget; 2016 May; 7(22):32433-48. PubMed ID: 27074572
[TBL] [Abstract][Full Text] [Related]
6. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
7. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
8. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
10. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNAs as biotargets in cisplatin-based drug resistance.
Abu N; Hon KW; Jeyaraman S; Jamal R
Future Oncol; 2018 Dec; 14(29):3085-3095. PubMed ID: 30468082
[TBL] [Abstract][Full Text] [Related]
12. Systematic identification of dysregulated lncRNAs associated with platinum-based chemotherapy response across 11 cancer types.
Zhu Y; Zhao Y; Dong S; Liu L; Tai L; Xu Y
Genomics; 2020 Mar; 112(2):1214-1222. PubMed ID: 31302201
[TBL] [Abstract][Full Text] [Related]
13. Tissue-based long non-coding RNAs "PVT1, TUG1 and MEG3" signature predicts Cisplatin resistance in ovarian Cancer.
El-Khazragy N; Mohammed HF; Yassin M; Elghoneimy KK; Bayoumy W; Hewety A; El Magdoub HM; Elayat W; Zaki W; Safwat G; Mosa M; Zedan K; Salem S; Bannunah AM; Mansy A
Genomics; 2020 Nov; 112(6):4640-4646. PubMed ID: 32781203
[TBL] [Abstract][Full Text] [Related]
14. Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles.
Murakami R; Matsumura N; Brown JB; Wang Z; Yamaguchi K; Abiko K; Yoshioka Y; Hamanishi J; Baba T; Koshiyama M; Mandai M; Yamada R; Konishi I
Gynecol Oncol; 2016 Apr; 141(1):49-56. PubMed ID: 27016229
[TBL] [Abstract][Full Text] [Related]
15. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
Marchion DC; Cottrill HM; Xiong Y; Chen N; Bicaku E; Fulp WJ; Bansal N; Chon HS; Stickles XB; Kamath SG; Hakam A; Li L; Su D; Moreno C; Judson PL; Berchuck A; Wenham RM; Apte SM; Gonzalez-Bosquet J; Bloom GC; Eschrich SA; Sebti S; Chen DT; Lancaster JM
Clin Cancer Res; 2011 Oct; 17(19):6356-66. PubMed ID: 21849418
[TBL] [Abstract][Full Text] [Related]
16. Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures.
Yu KH; Levine DA; Zhang H; Chan DW; Zhang Z; Snyder M
J Proteome Res; 2016 Aug; 15(8):2455-65. PubMed ID: 27312948
[TBL] [Abstract][Full Text] [Related]
17. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
Ferriss JS; Kim Y; Duska L; Birrer M; Levine DA; Moskaluk C; Theodorescu D; Lee JK
PLoS One; 2012; 7(2):e30550. PubMed ID: 22348014
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB
Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944
[TBL] [Abstract][Full Text] [Related]
19. Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.
Zhang S; Jing Y; Zhang M; Zhang Z; Ma P; Peng H; Shi K; Gao WQ; Zhuang G
Sci Rep; 2015 Nov; 5():16066. PubMed ID: 26530441
[TBL] [Abstract][Full Text] [Related]
20. The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma.
Lu E; Gareev I; Yuan C; Liang Y; Sun J; Chen X; Beylerli O; Sufianov A; Zhao S; Yang G
Curr Pharm Des; 2022; 28(23):1863-1869. PubMed ID: 35674307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
